FOLLOW US ON
The ECEF Hotline -
(732) 446-8520
About ECEF
President’s Message
ECEF Structure
Board of Directors
Medical Advisory Committee
Financial Statements
Resources
About This Disease
Esophagectomy Post Surgery Guide
Nutritional Guide Post Surgery
Articles
Services
Support Groups
Hours Hotline
Esophagectomy Post Surgical Guide
Get Involved
Donate Today
Research Projects
Events
DONATE »
JOIN »
Late Stage Cancer
June 16, 2025
Nivolumab Exhibits Enhanced DFS Outcomes in Resected Gastric Cancers
The FDA has approved a new combination regimen for certain patients with esophageal cell squamous cell carcinoma.
April 1, 2025
Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
November 19, 2024
ChemoRT Then Immunochemotherapy Then Surgery Promising in Unresectable Esophageal Cancer
November 16, 2024
Adding Immunotherapy to Neoadjuvant Chemoradiation May Improve Outcomes in Esophageal Cancer
November 13, 2024
Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer
September 3, 2024
Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma
September 1, 2024
Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma
July 26, 2024
ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer
May 21, 2024
The Drug Tevimbra Now Approved For Use in Esophageal Cancer– Finally Some Help For Patients In Great Need
April 26, 2024
Aspirin Linked to Lower Metastasis in Esophageal, Colorectal Cancers
April 4, 2024
FLOT vs CROSS in Resectable GEJ Adenocarcinoma: Which Regimen is Best?
Posts navigation
1
2
3
…
22
»